Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
PE Ratio 21.69
FVD's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 21.69 )
Ranked among companies with meaningful PE Ratio only.
FVD' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.71
Current: 21.69
0
21.71
PE Ratio without NRI 21.69
FVD's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 21.69 )
Ranked among companies with meaningful PE Ratio without NRI only.
FVD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.71
Current: 21.69
0
21.71
PB Ratio 2.75
FVD's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.75 )
Ranked among companies with meaningful PB Ratio only.
FVD' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.75
Current: 2.75
0
2.75

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.03
FVD's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.03 )
Ranked among companies with meaningful Dividend Yield % only.
FVD' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.03
Current: 2.03
0
2.03
5-Year Yield-on-Cost % 2.03
FVD's 5-Year Yield-on-Cost % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.03 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
FVD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.03
Current: 2.03
0
2.03

More Statistics

Short Percentage of Float0.00%
52-Week Range $25.57 - 29.45
Shares Outstanding (Mil)99,999,999.99
» More Articles for FVD

Headlines

Articles On GuruFocus.com
Lanka Bell Teams with IBM to Accelerate Cloud Adoption in Sri Lanka Apr 24 2017 
EXPRESS SCRIPTS ALERT: J&W Announces Investigation of Express Scripts; Expects to Lose Biggest Custo Apr 24 2017 
Infortrend Launches Cloud-integrated Unified Storage EonStor GSe Pro 2000 Supporting Multi-OS File S Apr 24 2017 
JD.com Announces Establishment of JD Logistics Business Group Apr 24 2017 
PreXion Adopts NetSuite OneWorld to Manage Business Transformation and Fuel Growth Apr 24 2017 
Sierra Bancorp Announces Agreement to Acquire OCB Bancorp of Ventura County Apr 24 2017 
Universal Technical Institute Schedules Fiscal 2017 Second Quarter Earnings Release and Conference C Apr 24 2017 
IBM and AIM Photonics Announce IP Licensing Agreement Apr 24 2017 
IBM Experts Discuss Artificial Intelligence Augmenting Human Intelligence and Creativity at 2017 Tri Apr 24 2017 
M.D.C. Holdings Declares Quarterly Cash Dividend Apr 24 2017 

More From Other Websites
Novartis’s 1Q17 Estimates: Innovative Medicines Segment Apr 21 2017
Why Sanofi’s Consumer Healthcare and Generics Segment Still Matters Apr 04 2017
Could Novartis’s CTL019 Capture Significant Market Share? Apr 04 2017
Are Sanofi’s Established Prescription Products Adding Up? Apr 03 2017
Novartis Expects to Witness Flat Revenue Growth in 2017 Apr 03 2017
Inside Sanofi’s Overall Revenue Performance in 2016 Mar 31 2017
Why Entresto Could Become Key Growth Driver for Novartis in 2017 Mar 30 2017
Novartis’s Valuation Compared to Its Peers’ Mar 24 2017
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds Mar 22 2017
What Will Drive AstraZeneca’s Oncology Revenues in 2017? Mar 22 2017
AstraZeneca’s New Products May Offer 2017 Growth Opportunities Mar 01 2017
Growth of AstraZeneca’s Oncology Segment in 2016 Mar 01 2017
A Dividend ETF On The Rise Feb 22 2017
These Prescription Products Matter to Sanofi’s Growth Feb 20 2017
Novartis’s Valuation after the 4Q16 Results Feb 03 2017
Inside Novartis’s Generics Performance in 4Q16 Feb 02 2017
Analysts Expect Negative Growth for Novartis in 4Q16 Jan 23 2017
How Did Novartis’s Innovative Medicines Segment Perform? Jan 17 2017
AstraZeneca’s Lynparza Is Still a Leading PARP Inhibitor in 2016 Jan 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK